The antibody-drug conjugate sacituzumab govitecan (IMMU-132) represents a potential novel therapeutic strategy in cholangiocarcinoma.

已完结 20 由 LLL 发布于 2025/10/10 16:04:36

DOI:10.1158/1535-7163.MCT-24-0972
作者：Racha Hosni,?Niklas Klümper,?Christine Sanders,?Sana Hosni,?Vittorio Branchi,?Alexander Semaan,?Abdullah Alajati,?Natalie Pelusi,?Susanna S Ng,?Damian J Ralser,?Saif-Eldin Abedellatif,?Hanno Matthaei
文献类型：期刊论文
补充材料：只需要正文

American Association for Cancer Research (AACR)

Abstract：Cholangiocarcinoma is a rare and aggressive cancer type with limited therapeutic options. Several novel antibody-drug conjugates (ADCs) have demonstrated promising anti-tumor activity in sol

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:其它数据库AMPKα2 signals amino acid insufficiency to inhibit protein synthesis